IDRA Share Price

Open 2.47 Change Price %
High 2.60 1 Day 0.07 2.82
Low 2.47 1 Week 0.46 22.01
Close 2.55 1 Month 0.68 36.36
Volume 5139299 1 Year 0.59 30.10
52 Week High 3.33
52 Week Low 1.19
IDRA Important Levels
Resistance 2 2.67
Resistance 1 2.62
Pivot 2.54
Support 1 2.48
Support 2 2.43
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
ASTI 0.00 0.00%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
MU 28.76 1.16%
MU 28.76 1.16%
MU 28.76 1.16%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
IPXL 12.70 37.30%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
RGLS 1.70 21.43%
SCON 1.54 19.38%
CPRX 2.01 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

IDRA Technical Analysis 5
As on 27th Mar 2017 IDRA Share Price closed @ 2.55 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.75 & Strong Buy for SHORT-TERM with Stoploss of 1.74 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDRA Target for March
1st Target up-side 2.16
2nd Target up-side 2.37
3rd Target up-side 2.58
1st Target down-side 1.58
2nd Target down-side 1.37
3rd Target down-side 1.16
IDRA Other Details
Segment EQ
Market Capital 20456252.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.iderapharma.com
IDRA Address
IDRA
167 Sidney Street
Cambridge, MA 02139
United States
Phone: 617-679-5500
Fax: 617-679-5592
IDRA Latest News
Interactive Technical Analysis Chart Idera Pharmaceuticals, Inc. ( IDRA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Idera Pharmaceuticals, Inc.
IDRA Business Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. During the year ended December 31, 2011, the Company collaborated with Merck Sharp & Dohme Corp., for the use of agonists of TLRs 7, 8, and 9 as vaccine adjuvants for cancer, infectious diseases, and Alzheimer�s disease. In November 2011, the Company reacquired rights to IMO-2055 from Merck KGaA, Darmstadt, Germany, its former collaborator.